Hartaj Singh
Stock Analyst at Oppenheimer
(1.45)
# 3,479
Out of 4,964 analysts
105
Total ratings
39.81%
Success rate
-10.78%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $30 → $37 | $18.34 | +101.74% | 13 | Jul 29, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $579.61 | +55.28% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $112.56 | +11.05% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $392.05 | - | 17 | Dec 19, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $6.53 | +328.79% | 6 | Nov 14, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $307.19 | +95.32% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $24.47 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $2.62 | +281.68% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.92 | +3,025.00% | 5 | May 30, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $1.88 | +378.72% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $2.46 | +1,526.02% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $5.65 | +289.38% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $16 | $3.41 | +369.21% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.92 | +33,754.17% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $24.42 | +22.85% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Outperform
Price Target: $30 → $37
Current: $18.34
Upside: +101.74%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $579.61
Upside: +55.28%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $112.56
Upside: +11.05%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $392.05
Upside: -
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $6.53
Upside: +328.79%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $307.19
Upside: +95.32%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $24.47
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $2.62
Upside: +281.68%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.92
Upside: +3,025.00%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.88
Upside: +378.72%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $2.46
Upside: +1,526.02%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $5.65
Upside: +289.38%
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $3.41
Upside: +369.21%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.92
Upside: +33,754.17%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $24.42
Upside: +22.85%